Toxoplasmosis in Cats: Pathogenesis, Diagnosis, and Zoonotic Implications

1. Introduction

Toxoplasmosis is a globally distributed protozoan infection caused by the obligate intracellular apicomplexan parasite Toxoplasma gondii. Felids, including the domestic cat (Felis catus), serve as the definitive hosts in which the parasite completes its sexual cycle and produces environmentally resistant oocysts [1, 2]. All warm-blooded vertebrates can serve as intermediate hosts, but only felids shed oocysts into the environment, making them the central reservoir for transmission [3, 4]. The infection has profound zoonotic implications, particularly for pregnant individuals, as primary infection during gestation can lead to congenital toxoplasmosis [5]. This article provides a detailed examination of the pathogenetic mechanisms, diagnostic modalities, and zoonotic risks associated with T. gondii infection in cats, with specific attention to the search term 'cat toxoplasmosis baby'.

2. Life Cycle and Pathogenesis in Cats

2.1. Definitive Host Cycle

The life cycle of T. gondii in the feline definitive host begins following ingestion of tissue cysts containing bradyzoites from intermediate hosts or, less efficiently, via ingestion of sporulated oocysts from the environment [6, 3]. Following ingestion, the parasite invades the small intestinal epithelium and undergoes a complex developmental program that includes multiple rounds of asexual proliferation followed by sexual differentiation [7, 6].

Recent single-cell transcriptomic studies have elucidated the detailed cellular dynamics of sexual development within the feline intestinal tract [6]. The pre-sexual stages, characterized as proliferating tachyzoite-like cells, undergo a developmental switch that commits them to sexual differentiation [7]. This process involves the formation of male and female gametocytes, fertilization, and the subsequent development of unsporulated oocysts that are shed in the feces [6, 8].

2.2. Oocyst Shedding Dynamics

Following primary infection, cats typically shed oocysts for 1 to 3 weeks, with a prepatent period of 3 to 10 days after tissue cyst ingestion and 18 days or longer after oocyst ingestion [8, 9]. The number of oocysts shed can reach millions per day, and a single cat may excrete over 100 million oocysts during the patent period [8]. Oocysts undergo sporulation in the environment within 1 to 5 days depending on temperature, humidity, and oxygen availability, becoming infectious to intermediate hosts [9, 4].

The ability of oocysts to survive under extreme environmental conditions is a critical factor in transmission epidemiology. Studies in the Brazilian semi-arid region have demonstrated that oocysts can remain viable for extended periods under natural dry season conditions, highlighting their environmental persistence [9].

2.3. Host-Parasite Interactions in the Feline Gut

Infection with T. gondii induces significant alterations in the feline intestinal microenvironment. Multi-omics approaches have revealed that the parasite modifies the gut microbiota composition and systemic metabolic profiles of infected cats [10]. The dynamic landscape of microRNA expression in the feline small intestine during infection reflects host regulatory responses aimed at controlling parasite replication while managing inflammatory damage [11].

The parasite expresses specific proteins that facilitate entero-epithelial invasion and colonization. Microneme protein 17A (MIC17A) has been identified as a potential marker for both entero-epithelial and chronic stage infection [12]. Additionally, the dense granule protein GRA12 has been evaluated as a vaccine antigen, demonstrating that the host immune system can be primed to reduce oocyst shedding [13].

2.4. Disseminated Infection and Clinical Pathogenesis

Following intestinal invasion, tachyzoites disseminate via the lymphatic and hematogenous routes to various tissues, including the central nervous system, eyes, skeletal muscle, and myocardium [14, 15]. The parasite converts to bradyzoite-containing tissue cysts under immune pressure, establishing a chronic latent infection that persists for the life of the host [16].

In immunocompetent cats, clinical disease is typically mild or subclinical [16, 15]. However, in immunocompromised individuals, particularly those co-infected with feline immunodeficiency virus (FIV) or feline leukemia virus (FeLV), severe disseminated disease can occur [17, 14]. A fatal case of disseminated toxoplasmosis has been documented in a cat co-infected with FeLV-C subgroup, and the isolate was characterized as a mouse-virulent recombinant type I/III strain [17]. Similarly, toxoplasmal meningoencephalitis has been reported in shelter cats with presumed concurrent feline infectious peritonitis [14].

3. Clinical Signs

3.1. Acute Disease Manifestations

Clinical signs of acute toxoplasmosis in cats are highly variable and depend on the organ systems affected [16, 14]. The most common presentations include:

• Fever that is unresponsive to antibiotic therapy
• Lethargy and anorexia
• Respiratory signs including tachypnea and dyspnea due to pneumonitis
• Ocular signs such as uveitis, chorioretinitis, and anterior chamber inflammation
• Neurologic signs including ataxia, seizures, circling, and behavioral changes

Clinical presentation can mimic other diseases, leading to diagnostic challenges [14]. Fatal disseminated infections manifest with multi-organ failure involving the lungs, liver, and central nervous system [15].

3.2. Subclinical and Chronic Infection

The majority of infected cats remain asymptomatic [16]. Chronic infection is characterized by the persistence of tissue cysts, primarily in the brain and skeletal muscle. Reactivation of latent infection can occur during periods of immunosuppression, leading to recrudescent disease [17, 14].

3.3. Role of Coinfections

Coinfection with hemotropic pathogens and other parasites is common in endemic regions. Studies have demonstrated significant interactions between T. gondii and hemotropic Mycoplasma species in cats [18]. The presence of coinfections can complicate clinical diagnosis and influence disease progression.

4. Diagnostic Approaches

Diagnosis of feline toxoplasmosis requires a combination of serological, molecular, and histopathological methods [16]. No single test provides definitive diagnosis in all clinical contexts.

4.1. Serological Methods

Serological detection of anti-T. gondii antibodies is the most commonly employed diagnostic approach [19, 2, 20]. The indirect immunofluorescence antibody test (IFAT) and enzyme-linked immunosorbent assay (ELISA) are used to detect IgM and IgG antibodies [19, 2, 20].

Recent advances include the development of double-antigen sandwich colloidal gold immunochromatographic strips for detection of antibodies across multiple host species, providing rapid field-deployable testing [19]. Sandwich ELISA methods targeting circulating parasite antigens, such as fructose-1,6-bisphosphate aldolase (ALD), have been established for direct detection of active infection [21].

Seroprevalence studies provide valuable epidemiological data. Global seroprevalence rates vary widely, with reported values of 18.5% in urban client-owned cats in Kazakhstan [20], 26.7% in Hong Kong [1], and up to 42% in stray cat populations in Brazil [22]. Risk factors for seropositivity include age, outdoor access, raw meat consumption, and living in multi-cat households [1, 2, 22].

4.2. Molecular Detection

Polymerase chain reaction (PCR) assays offer high sensitivity and specificity for detecting T. gondii DNA in clinical specimens [23, 24, 25]. Real-time PCR targeting the B1 gene or 529 bp repetitive element is considered the gold standard for molecular detection [23, 24].

An antisense PCR assay has been developed specifically for detection of T. gondii in domestic cats, demonstrating improved sensitivity compared to conventional PCR [24]. Fecal PCR is useful for identifying oocyst shedding, though it must be distinguished from the closely related coccidian Hammondia hammondi [25]. Genotyping approaches have enabled differentiation of T. gondii from H. hammondi in feline fecal samples [25].

Detection of T. gondii DNA in reproductive tissues from cats enrolled in neutering programs has revealed that parasite DNA can be present in gonadal and uterine tissues, raising questions about potential vertical transmission [26].

4.3. Oocyst Detection in Feces

Microscopic examination of fecal samples using fecal flotation techniques can identify oocysts, but sensitivity is limited due to intermittent shedding and morphological similarity to other coccidians [8, 25]. Specific ELISA methods for detecting oocyst antigens in feces have been optimized to improve diagnostic accuracy [27].

4.4. Advanced Diagnostic Technologies

Comprehensive diagnostic algorithms that integrate traditional methods with emerging technologies have been proposed [16]. These approaches incorporate multiple diagnostic modalities:

4.5. Diagnostic Decision Algorithm

The following Mermaid diagram summarizes a recommended diagnostic workflow for feline toxoplasmosis:

flowchart TD
    A[Clinical suspicion of toxoplasmosis], > B{Clinical signs present?}
    B, >|Yes| C[Perform serology: IgM and IgG]
    B, >|No| D[Incidental finding: screening]
    D, > E[Serology: IgG only]
    C, > F{IgM positive?}
    F, >|Yes| G[Probable acute infection: PCR blood/fecal]
    F, >|No| H{IgG positive?}
    H, >|Yes| I[Chronic/latent infection: no further testing]
    H, >|No| J[Seronegative: alternative diagnosis]
    G, > K{PCR positive?}
    K, >|Yes| L[Confirm active infection: treat]
    K, >|No| M[Probable recent infection: repeat serology in 2-4 weeks]
    L, > N[Monitor oocyst shedding: fecal PCR/flotation]
    N, > O[Shedding confirmed: environmental precautions]

5. Treatment and Management

5.1. Antiprotozoal Therapy

Treatment of clinical toxoplasmosis in cats typically involves a combination of clindamycin (10-12 mg/kg orally every 12 hours for 4 weeks) or pyrimethamine combined with sulfonamides [16]. Clindamycin is the drug of choice and acts by inhibiting protein synthesis in the parasite's apicoplast. Treatment should continue for several days beyond resolution of clinical signs.

5.2. Supportive Care

Supportive care including fluid therapy, nutritional support, and control of secondary infections is critical in severe cases [14, 15]. Corticosteroids may be indicated for ocular toxoplasmosis to control inflammatory damage but should be used cautiously in the context of systemic infection.

5.3. Vaccination Strategies

Several vaccine candidates have been evaluated in experimental settings. A live-attenuated T. gondii Pru mutant lacking the PP2A-c phosphatase subunit (PruΔpp2a-c) elicited protective immunity in mice and cats [28]. Recombinant GRA12 vaccines and DNA vector plasmids encoding the ROP18 partial gene have demonstrated immunogenicity in cats, although further optimization is required before clinical deployment [13, 29].

6. Zoonotic Implications

6.1. Transmission to Humans

Humans typically acquire T. gondii infection through ingestion of tissue cysts in undercooked meat, consumption of food or water contaminated with sporulated oocysts, or congenital transmission from mother to fetus [5, 4]. Cats are the only definitive host that sheds oocysts into the environment, making them a key risk factor for human infection, particularly for pregnant individuals [5, 3].

6.2. Congenital Toxoplasmosis and the Search Term "Cat Toxoplasmosis Baby"

Primary maternal infection acquired during pregnancy can result in transplacental transmission of tachyzoites to the fetus, leading to congenital toxoplasmosis [5]. The risk of fetal infection increases with gestational age, but the severity of disease is greater when infection occurs in the first trimester. Clinical manifestations in congenitally infected infants include chorioretinitis, intracranial calcifications, hydrocephalus, and neurodevelopmental deficits.

The search term 'cat toxoplasmosis baby' reflects widespread concern regarding the risk to infants posed by feline companionship during pregnancy [5]. It is critical for veterinary professionals to provide accurate, evidence-based guidance. The primary risk to pregnant women is not from direct contact with a healthy, immunocompetent cat but rather from environmental contamination with sporulated oocysts [5, 4]. Indoor-only cats that are not fed raw meat and have no access to intermediate hosts have a very low probability of shedding oocysts [20, 30].

6.3. Prevention of Zoonotic Transmission

Comprehensive prevention strategies include:

• Pregnant individuals should avoid cleaning litter boxes; if unavoidable, daily scooping and hand hygiene are essential
• Litter boxes should be cleaned daily before oocysts sporulate (within 24-48 hours)
• Cats should be kept indoors and fed commercial cooked or canned food
• Gloves should be worn during gardening, and vegetables should be washed thoroughly
• Raw or undercooked meat should be avoided by pregnant individuals
• Hand hygiene after handling soil, sand, or raw meat is critical

Public health messaging should emphasize that the cat itself is not inherently dangerous, and unnecessary relinquishment of cats during pregnancy is not supported by evidence [5].

7. Epidemiological Considerations

7.1. Global Seroprevalence

Seroprevalence of T. gondii in domestic cats varies considerably by geographic region, management practices, and sampling methodology. In addition to the aforementioned rates in Kazakhstan [20] and Hong Kong [1], high seroprevalence has been reported in stray populations in Thailand [23], Jordan [2], and Brazil [31, 22]. Wild felid populations also exhibit exposure, as demonstrated in Polish wild felids [32] and northern fur seal habitats in Alaska, where domestic cats serve as a bridging reservoir [33].

7.2. Environmental and Landscape Factors

Landscape variables influence T. gondii exposure risk in both domestic and wild animals. Studies in the Valdivian Temperate Rainforest of Chile have identified associations between land use patterns and seroprevalence in cats [30]. Spatial epidemiological approaches in Brazil have demonstrated clustering of seropositive cats in peri-urban areas with high population density [22].

7.3. Transmission Modeling

Mathematical modeling of T. gondii transmission dynamics in agricultural landscapes has provided insights into the relative contributions of domestic cat populations and wildlife reservoirs to environmental oocyst contamination [4]. These models underscore the importance of managing cat populations to reduce environmental contamination.

8. One Health Perspectives

Toxoplasmosis exemplifies the One Health concept, linking veterinary medicine, human medicine, and environmental health. The domestic cat serves as the nexus of transmission, connecting wildlife reservoirs to human populations [31, 3, 30]. Management of this zoonosis requires interdisciplinary collaboration.

Reproductive tissue testing from neutering programs has demonstrated that T. gondii DNA can be detected in gonadal tissues, which has implications for tissue handling and surgical biosafety [26]. Additionally, the finding that T. gondii can alter feline behavior to potentially increase predation risk and transmission efficiency, known as "fatal feline attraction," has evolutionary implications for parasite-host dynamics [3].

9. Conclusions

Toxoplasmosis in cats represents a complex interplay of parasite biology, host immunity, and environmental factors. The cat is both the definitive host essential for parasite sexual reproduction and the primary source of environmental contamination with oocysts. Diagnosis requires a multimodal approach incorporating serology, molecular detection, and fecal examination. The zoonotic risk, particularly during pregnancy, is real but manageable with appropriate precautions. Veterinary professionals play a critical role in educating cat owners and implementing preventive strategies to reduce the risk of congenital toxoplasmosis.

References

[1] Elsohaby I, Zubair M, Baqar Z, et al. Seroprevalence of Toxoplasma gondii and associated demographic factors in privately-owned dogs, cats, and community cats in Hong Kong. BMC Vet Res. 2026. https://pubmed.ncbi.nlm.nih.gov/42135800/

[2] Alkhatatbeh SK, Lafi SQ, Hammad HB, et al. The first seroprevalence and molecular detection of toxoplasmosis infecting cats in Jordan with associated risk factors. Vet Parasitol Reg Stud Reports. 2026. https://pubmed.ncbi.nlm.nih.gov/41741047/

[3] Webster JP. Who makes the decisions? Uncovering the evolutionary implications and clinical applications of Toxoplasma gondii's Fatal Feline Attraction. Folia Parasitol. 2025. https://pubmed.ncbi.nlm.nih.gov/40458021/

[4] Binny RN, Hickling GJ, James A, et al. Modelling transmission and control of Toxoplasma gondii in New Zealand farmland. R Soc Open Sci. 2025. https://pubmed.ncbi.nlm.nih.gov/39911889/

[5] Gharbi M, Yera H, Dupouy-Camet J. [The cat, the women and the toxoplasma: What advice should be given to a pregnant woman who is seronegative for toxoplasmosis and owns a cat?]. Gynecol Obstet Fertil Senol. 2026. https://pubmed.ncbi.nlm.nih.gov/41628830/

[6] Alrubaye HS, Reilly SM, da Silva R, et al. A single-cell atlas of Toxoplasma sexual development in the feline intestinal tract. Nat Microbiol. 2026. https://pubmed.ncbi.nlm.nih.gov/42020723/

[7] Sena F, Hakimi M-A, Francia ME. Proliferating toward sex: characterization of cell division of Toxoplasma gondii's pre-sexual stages. mBio. 2026. https://pubmed.ncbi.nlm.nih.gov/42153709/

[8] Zhao GH, Zhou BB, Cao ZH, et al. The development and excretion of Toxoplasma gondii oocyst manipulate the gut microbiota in its definitive host. Parasit Vectors. 2025. https://pubmed.ncbi.nlm.nih.gov/40635073/

[9] Silva ALP, Lima BA, Formiga VHAS, et al. Survival and viability of Toxoplasma gondii oocysts under natural dry season conditions in the Brazilian semi-arid region. Vet Res Commun. 2025. https://pubmed.ncbi.nlm.nih.gov/40332642/

[10] Zhao JX, Wang XY, Zhang X, et al. Toxoplasma gondii alters gut microbiota and systemic metabolism in cats: A multi-omics approach. Vet J. 2025. https://pubmed.ncbi.nlm.nih.gov/41015376/

[11] Zhai B, Bao B, Xie SC, et al. Dynamic landscape of microRNA expression in the feline small intestine during Toxoplasma gondii infection. Parasit Vectors. 2026. https://pubmed.ncbi.nlm.nih.gov/41965856/

[12] Günay-Esiyok Ö, Koçkaya ES, Yılmaz R, et al. The Potential of MIC17A both as an Entero-epithelial and Chronic Stage Marker for Detection of Feline Toxoplasmosis. Curr Microbiol. 2026. https://pubmed.ncbi.nlm.nih.gov/41874672/

[13] Yang J, Nie L, Song Y, et al. Immunogenicity and Protective Efficacy of a Recombinant Toxoplasma gondii GRA12 Vaccine in Domestic Cats. Vaccines (Basel). 2025. https://pubmed.ncbi.nlm.nih.gov/40872935/

[14] Abdu A, Henry ME, André NM, et al. Toxoplasmal meningoencephalitis in a 14 week-old shelter cat with presumed feline infectious peritonitis. Vet Parasitol Reg Stud Reports. 2025. https://pubmed.ncbi.nlm.nih.gov/39855861/

[15] Real L, Barneto A, Kortabarria N, et al. Fatal disseminated Toxoplasma gondii infection in a cat from Madrid, Spain. JFMS Open Rep. 2025. https://pubmed.ncbi.nlm.nih.gov/39764240/ *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

[16] Zhao D, Liao Y, Liu H, et al. Comprehensive diagnostic approaches to feline toxoplasmosis: Bridging traditional methods and emerging technologies. Virulence. 2025. https://pubmed.ncbi.nlm.nih.gov/40974007/

[17] Fonseca J, Almeida P, Campos S, et al. Identification of a mouse-virulent recombinant type I/III Toxoplasma gondii strain in liver cytology of an immunosuppressed cat infected with FeLV-C subgroup. Vet Res Commun. 2025. https://pubmed.ncbi.nlm.nih.gov/41108469/

[18] Ríos-Úsuga C, Rendón-Ramos LM, Jaramillo-Delgado IL, et al. Disclosing coinfections: The interaction between Toxoplasma gondii and hemotropic agents in Colombian dogs and cats. Comp Immunol Microbiol Infect Dis. 2025. https://pubmed.ncbi.nlm.nih.gov/40712328/

[19] Mu X, Chen C, Pu X, et al. Development and Field Validation of a Double-Antigen Sandwich Colloidal Gold Immunochromatographic Strip for Detection of Toxoplasma gondii Antibodies in Multiple Host Species. Transbound Emerg Dis. 2026. https://pubmed.ncbi.nlm.nih.gov/42253330/

[20] Lider LA, Kiyan V, Mannapova NE, et al. Seroprevalence of Toxoplasma gondii infection in urban client-owned cats in Kazakhstan. Vet Res Commun. 2025. https://pubmed.ncbi.nlm.nih.gov/40875169/

[21] Gong JZ, Fan YM, Wu YP, et al. Establishment and application of a sandwich ELISA method for measuring Toxoplasma gondii circulating fructose-1,6-bisphosphate aldolase (ALD) protein in cats. Vet Parasitol. 2025. https://pubmed.ncbi.nlm.nih.gov/39813886/

[22] Murata FHA, Barboza JP, Tasso FF, et al. Prevalence and spatial distribution of Toxoplasma gondii infection in domestic and stray cats (Felis catus) in Northwestern São Paulo, Brazil. Spat Spatiotemporal Epidemiol. 2025. https://pubmed.ncbi.nlm.nih.gov/40935507/

[23] Kengradomkij C, Chimnoi W, Kamyingkird K, et al. PCR detection of Toxoplasma gondii DNA in fecal samples from stray cats in Bangkok Metropolitan, Thailand. Food Waterborne Parasitol. 2026. https://pubmed.ncbi.nlm.nih.gov/42094705/

[24] Li YY, Bai SY, Yu HQ, et al. Development and evaluation of an antisense PCR assay for Toxoplasma gondii detection in domestic cats. Vet Parasitol. 2026. https://pubmed.ncbi.nlm.nih.gov/41724116/

[25] Jańczak D, Stryjek R, Maj AK, et al. PCR Detection, Genotyping, and Differentiation of Toxoplasma gondii from Hammondia hammondi Excreted in the Feces of Cats in Poland Between 2020 and 2024. Pathogens. 2025. https://pubmed.ncbi.nlm.nih.gov/40430763/

[26] Murata FHA, Barboza JP, de Souza CAG, et al. Investigation of Toxoplasma gondii in reproductive tissues of companion animals from a municipal neutering program. Vet Parasitol Reg Stud Reports. 2026. https://pubmed.ncbi.nlm.nih.gov/41651631/

[27] He M, Zhang B, Han S, et al. Development and optimization of an ELISA method to detect Toxoplasma gondii oocyst infection in cats. Parasitol Res. 2025. https://pubmed.ncbi.nlm.nih.gov/40619535/

[28] Xie SC, Lv YH, Wang M, et al. Live-attenuated Toxoplasma gondii PruΔpp2a-c mutant elicits protective immunity against toxoplasmosis in mice and cats. Int J Parasitol. 2026. https://pubmed.ncbi.nlm.nih.gov/40783178/

[29] Minutti AF, Sasse JP, Dos Santos Silva AC, et al. Evaluation of a DNA vector plasmid encoding a partial rop18 gene from toxoplasma gondii in domestic cats as a vaccine candidate. Vaccine. 2025. https://pubmed.ncbi.nlm.nih.gov/40054140/

[30] Calvo-Mac C, Delgado-Parada N, Muñoz-Zanzi C, et al. Landscape Variables Associated with Toxoplasma gondii Exposure in American Mink (Neogale vison) and Domestic Cats (Felis catus) in the Valdivian Temperate Rainforest, Chile. J Wildl Dis. 2025. https://pubmed.ncbi.nlm.nih.gov/40374172/

[31] Bazan L, Argibay HD, Borges-Silva W, et al. Seroprevalence and risk factors for Toxoplasma gondii infection in wild, domestic and companion animals in urban informal settlements from Salvador, Brazil. PLoS Negl Trop Dis. 2025. https://pubmed.ncbi.nlm.nih.gov/41401226/

[32] Didkowska A, Kołodziej-Sobocińska M, Matusik K, et al. Toxoplasma gondii in wild felides in Poland. BMC Vet Res. 2025. https://pubmed.ncbi.nlm.nih.gov/41387866/

[33] Dawant T, Gerhold R, Scott D, et al. Toxoplasma gondii infection in domestic cats and northern fur seals of the Pribilof Islands, Alaska. Int J Parasitol Parasites Wildl. 2025. https://pubmed.ncbi.nlm.nih.gov/40584261/

[34] Spada E, Tattarletti G, Proverbio D, et al. The AB Blood Group System Phenotype Does Not Play a Role in Toxoplasma gondii Infection in Cats. Pathogens. 2025. https://pubmed.ncbi.nlm.nih.gov/41471183/

[35] Schanz ML, Zhao F, Zadeii KE, et al. The cat's out of the bag: Toxoplasma gondii provides further insight into myeloid-mediated host defense. Immunohorizons. 2025. https://pubmed.ncbi.nlm.nih.gov/40854593/